Trump announces trade deal with EU following months of negotiations
Investing.com - Recursion Pharmaceuticals reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Recursion Pharmaceuticals announced earnings per share of $-0.35 on revenue of $13.05M. Analysts polled by Investing.com EPS of $-0.39 on revenue of $6.96M.
Recursion Pharmaceuticals 's are down 48.09% and is trading at $9.60 , still down 54.69% from its 52 week high of $21.19 set on Tuesday, December 7, 2021.
Recursion Pharmaceuticals follows other major Healthcare sector earnings this month
Recursion Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar